(AGEN) Agenus - Overview
Stock: Antibody, Adjuvant, Vaccine, Oncology, Immunotherapy
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 109% |
| Relative Tail Risk | -11.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.22 |
| Alpha | -44.77 |
| Character TTM | |
|---|---|
| Beta | 1.391 |
| Beta Downside | 0.964 |
| Drawdowns 3y | |
|---|---|
| Max DD | 96.55% |
| CAGR/Max DD | -0.62 |
Description: AGEN Agenus January 17, 2026
Agenus Inc. (NASDAQ: AGEN) is a clinical-stage biotech focused on harnessing the immune system to fight cancer and infectious diseases. Its core technologies include the Retrocyte Display antibody-discovery platform and the QS-21 Stimulon vaccine adjuvant, both aimed at generating fully human or humanized monoclonal antibodies.
The pipeline features a mix of checkpoint inhibitors and novel immunomodulators: Balstilimab (PD-1 blocker), AGEN1181 (Fc-enhanced CTLA-4 blocker in Phase 2 for mCRC, pancreatic cancer, and melanoma), AGEN2373 (CD137 agonist in Phase 1b), AGEN1423 (CD73/TGF-β TRAP), AGEN1571 (ILT2), and BMS-986442 (TIGIT bispecific). Additional candidates such as INCAGN1876 (GITR agonist), INCAGN2390 (TIM-3), INCAGN2385 (LAG-3), MK-4830 (ILT4), and UGN-301 (intravesical zalifrelimab) broaden the immuno-oncology portfolio.
Strategic collaborations with large pharma-Bristol-Myers Squibb, Gilead, Merck, Incyte, and others-provide both development funding and potential commercialization pathways, mitigating some cash-flow risk for a company that reported roughly $140 million of cash and cash equivalents at the end of Q4 2023.
Key sector drivers include the projected >$200 billion global immuno-oncology market by 2028 and accelerating FDA approvals for checkpoint-inhibitor combinations, which could create a favorable environment for Agenus’s multi-target approach.
Recent performance metrics show R&D spending at ~30 % of revenue in 2023, and the company’s cash burn rate of ~$45 million per quarter, underscoring the importance of upcoming data readouts (e.g., AGEN1181 Phase 2 results expected Q3 2024) for liquidity planning.
For a deeper, data-driven assessment of Agenus’s valuation and risk profile, consider exploring the analyst tools on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: -35.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.38 > 0.02 and ΔFCF/TA 33.43 > 1.0 |
| NWC/Revenue: -143.4% < 20% (prev -137.4%; Δ -5.95% < -1%) |
| CFO/TA -0.38 > 3% & CFO -89.2m > Net Income -35.2m |
| Net Debt (42.3m) to EBITDA (33.3m): 1.27 < 3 |
| Current Ratio: 0.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (32.9m) vs 12m ago 52.47% < -2% |
| Gross Margin: 0.08% > 18% (prev 0.07%; Δ 0.65% > 0.5%) |
| Asset Turnover: 45.23% > 50% (prev 67.27%; Δ -22.04% > 0%) |
| Interest Coverage Ratio: 0.34 > 6 (EBITDA TTM 33.3m / Interest Expense TTM 59.9m) |
Altman Z'' -15.00
| A: -0.65 (Total Current Assets 133.9m - Total Current Liabilities 287.1m) / Total Assets 233.9m |
| B: -9.29 (Retained Earnings -2.17b / Total Assets 233.9m) |
| C: 0.09 (EBIT TTM 20.7m / Avg Total Assets 236.2m) |
| D: -4.22 (Book Value of Equity -2.17b / Total Liabilities 514.8m) |
| Altman-Z'' Score: -38.42 = D |
Beneish M 1.00
| DSRI: 45.44 (Receivables 6.26m/207.0k, Revenue 106.8m/160.4m) |
| GMI: 91.93 (GM 0.08% / 7.40%) |
| AQI: 2.20 (AQ_t 0.32 / AQ_t-1 0.15) |
| SGI: 0.67 (Revenue 106.8m / 160.4m) |
| TATA: 0.23 (NI -35.2m - CFO -89.2m) / TA 233.9m) |
| Beneish M-Score: 116.6 (Cap -4..+1) = D |
What is the price of AGEN shares?
Over the past week, the price has changed by +3.52%, over one month by -15.27%, over three months by -23.44% and over the past year by -21.39%.
Is AGEN a buy, sell or hold?
- StrongBuy: 1
- Buy: 1
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the AGEN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 12.3 | 319.4% |
| Analysts Target Price | 12.3 | 319.4% |
| ValueRay Target Price | 1.6 | -46.3% |
AGEN Fundamental Data Overview February 05, 2026
P/S = 0.9811
P/B = 218.6149
Revenue TTM = 106.8m USD
EBIT TTM = 20.7m USD
EBITDA TTM = 33.3m USD
Long Term Debt = 23.6m USD (from longTermDebt, last quarter)
Short Term Debt = 11.8m USD (from shortTermDebt, last quarter)
Debt = 45.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 42.3m USD (from netDebt column, last quarter)
Enterprise Value = 147.1m USD (104.8m + Debt 45.8m - CCE 3.46m)
Interest Coverage Ratio = 0.34 (Ebit TTM 20.7m / Interest Expense TTM 59.9m)
EV/FCF = -1.65x (Enterprise Value 147.1m / FCF TTM -89.3m)
FCF Yield = -60.70% (FCF TTM -89.3m / Enterprise Value 147.1m)
FCF Margin = -83.60% (FCF TTM -89.3m / Revenue TTM 106.8m)
Net Margin = -32.92% (Net Income TTM -35.2m / Revenue TTM 106.8m)
Gross Margin = 0.08% ((Revenue TTM 106.8m - Cost of Revenue TTM 106.7m) / Revenue TTM)
Gross Margin QoQ = 19.83% (prev -4.91%)
Tobins Q-Ratio = 0.63 (Enterprise Value 147.1m / Total Assets 233.9m)
Interest Expense / Debt = 28.77% (Interest Expense 13.2m / Debt 45.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = 16.3m (EBIT 20.7m * (1 - 21.00%))
Current Ratio = 0.47 (Total Current Assets 133.9m / Total Current Liabilities 287.1m)
Debt / Equity = -0.17 (negative equity) (Debt 45.8m / totalStockholderEquity, last quarter -274.1m)
Debt / EBITDA = 1.27 (Net Debt 42.3m / EBITDA 33.3m)
Debt / FCF = -0.47 (negative FCF - burning cash) (Net Debt 42.3m / FCF TTM -89.3m)
Total Stockholder Equity = -324.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -14.89% (Net Income -35.2m / Total Assets 233.9m)
RoE = 10.85% (negative equity) (Net Income TTM -35.2m / Total Stockholder Equity -324.2m)
RoCE = -6.87% (negative capital employed) (EBIT 20.7m / Capital Employed (Equity -324.2m + L.T.Debt 23.6m))
RoIC = -5.62% (NOPAT 16.3m / Invested Capital -290.5m)
WACC = 14.59% (E(104.8m)/V(150.6m) * Re(11.04%) + D(45.8m)/V(150.6m) * Rd(28.77%) * (1-Tc(0.21)))
Discount Rate = 11.04% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 29.09%
Fair Price DCF = unknown (Cash Flow -89.3m)
EPS Correlation: -66.56 | EPS CAGR: -9.67% | SUE: -4.0 | # QB: 0
Revenue Correlation: 24.05 | Revenue CAGR: 11.27% | SUE: -2.28 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.80 | Chg30d=N/A | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=1.96 | Chg30d=+1.705 | Revisions Net=+1 | Growth EPS=+150.8% | Growth Revenue=+66.1%